Sira 74
Alternative Names: Sira-74Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator Siragen Pharmaceuticals
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neurodegenerative disorders
Highest Development Phases
- Discontinued Neurodegenerative disorders
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 08 Jul 2016 Sira 74 is available for licensing as of 08 Jul 2016. https://siragen.com/